Steven A. Feldman, Ph.D.
Dr. Feldman directs the Surgery Branch Vector Production Facility, which develops and manufactures cGMP quality retroviral and lentiviral vectors encoding T cell receptors or chimeric antigen receptors for the ex vivo genetic modification of T lymphocytes in support of the Branch’s clinical efforts utilizing adoptive cell transfer for the treatment of patients with solid cancers and hematologic malignancies. Dr. Feldman’s research interests also include development of retroviral and lentiviral packaging cell lines and novel strategies for the large-scale closed cell culture processes to support production of clinical reagents. As a result, the lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors. Recently, research efforts have been focused on individualized cell therapies targeting immunogenic mutations presented on breast cancers.
- cGMP manufacture of retro/lentiviral vectors encoding T cell or chimeric antigen receptors for ex vivo gene-engineering of T lymphocytes.
- Development of novel strategies for gene engineering T lymphocytes (retroviral, lentiviral, transposon, gene editing) as well as clinical-scale vector and cell production platforms.
- Identification of T cell or chimeric antigen receptors targeting novel tumor antigens on solid cancers.
- Identification of immunogenic mutations (neoantigens) on breast tumors for an individualized cell therapy.
- Novel methods to improve T lymphocyte function and introduce T cell or chimeric antigen receptors using gene editing techniques.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.The Lancet. 385(9967): 517-528, 2015. [ Journal Article ]
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response.Clin. Cancer Res.. 21(5): 1019-1027, 2015. [ Journal Article ]
A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes.Hum Gene Ther. Methods. 23(2): 73-83, 2012. [ Journal Article ]
Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.Hum Gene Ther.. 22(1): 107-115, 2011. [ Journal Article ]
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.Mol Ther. 23(8): 1380-90, 2015. [ Journal Article ]
Dr. Feldman received his B.A., M.P.H., and Ph.D. from University of California, Berkeley. As a National Reseach Council fellow, he studied mechanisms of viral entry at the FDA's Centers for Biologics Evaluation and Research followed by an addtional NIH fellowhsip investigating the mechanisms of retroviral entry into host cells. Dr. Feldman then spent three years at a leading biotechnology company as the Senior Scientist in charge of process development for the manufacturing of viral vectors and vaccines before coming back to the Surgery Branch of the National Cancer Institute to establish a new Retro/Lentiviral Vector Core Facility.
|Mary Black||Research Biologist|
|Harshini Chinnasamy||Postbaccalaureate Fellow|
|Ornela Dervishaj M.D.||Clinical Fellow|
|Isaac Kriley M.D.||Clinical Fellow|
|Hui Xu||Research Biologist|
|Nikolaos Zacharakis Ph.D.||Research Fellow|